Trials / Recruiting
RecruitingNCT07277660
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Galvokimig | Drug: Galvokimig Pharmaceutical form: Solution for injection |
| DRUG | Placebo | Drug: Placebo Pharmaceutical form: Solution for injection |
Timeline
- Start date
- 2025-12-29
- Primary completion
- 2027-05-17
- Completion
- 2028-03-06
- First posted
- 2025-12-11
- Last updated
- 2026-03-27
Locations
23 sites across 3 countries: United States, Canada, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07277660. Inclusion in this directory is not an endorsement.